Seer, Inc. Company profile
About Seer Inc
Seer, Inc. is a life sciences technology company. The Company enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The Company's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Seer Inc revenues increased from $656K to $6.6M. Net loss increased from $32.8M to $71.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase from $8.9M to $26.1M (expense), Stock-based compensation in General and increase from $6.4M to $19.7M (expense).
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)